Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Aug 14 2020

Full Issue

Track The Vaccine Race: 25 In Human Trials, Many More In Development

The Washington Post and CNN both offer up handy graphics explaining the status of and science behind nearly 200 experimental vaccines so far proposed. But the lack of diversity in those clinical trials raises concerns.

The Washington Post: These Are The Top Coronavirus Vaccines To Watch

The worldwide effort to create a vaccine for the novel coronavirus kicked off in January, soon after scientists in China posted online the genome of a virus causing a mysterious pneumonia. Vaccine development usually takes years and unfolds step by step. Experimental vaccine candidates are created in the laboratory and tested in animals before moving into progressively larger human clinical trials. These steps are now overlapping in the race to find a vaccine for a global disease that has killed hundreds of thousands of people. (8/13)

CNN: Inside The Multibillion Dollar Race For A Vaccine

Four years. That’s the fastest a vaccine has ever been developed -- and most take 10 to 15. But scientists are now racing to do it in under one. Dozens of research teams around the world are working to develop a vaccine for SARS-CoV-2, the virus that causes Covid-19, using a mix of established techniques and new technologies. (Mackintosh, Mezzofiore and Polglase, 8/14)

Stat: Covid-19 Clinical Trials Are Failing To Enroll Diverse Populations

It’s been well-established that Covid-19, at least in the United States, has disproportionately affected people of color. And yet clinical trials of treatments and vaccines for Covid-19 have so far failed to enroll diverse populations that actually reflect society. (Feuerstein, Garde and Robbins, 8/14)

Vox: These Covid-19 Vaccine Candidates Could Change The Way We Make Vaccines — If They Work

As urgency mounts for a Covid-19 coronavirus vaccine, a key question for scientists is whether this pandemic will be the watershed moment for two new technologies that have never before seen widespread use in humans. If proven effective, these approaches could dramatically speed up the development of other new vaccines and drastically lower costs, heralding a new era in the fight against infectious disease. (Ifran, 8/13)

And vaccine developments from overseas —

Reuters: China Sinopharm's Potential COVID-19 Vaccine Triggers Antibodies In Clinical Trials: Journal

A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said. The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval. (8/14)

AP: Indonesia Takes Part In Late-Stage China Vaccine Trial

More people in Indonesia rolled up their sleeves Friday to test a potential coronavirus vaccine developed by a Chinese company. The Indonesian government announced the partnership between state-owned enterprise Bio Farma and the Chinese company Sinovac BioTech in early July. As part of the deal, Indonesia recruited 1,620 volunteers for the trial. The first 20 were injected with the candidate vaccine in Bandung, West Java province, on Tuesday, and more followed suit. (Tarigan and Milko, 8/14)

Reuters: UK Buys More Potential COVID-19 Vaccines From J&J And Novavax 

Britain will buy potential COVID-19 vaccines from U.S. drugmakers Johnson & Johnson (JNJ.N) and Novavax Inc (NVAX.O), the companies said on Friday, bringing the total number of deals by the UK government to six as the race for shots heats up. Johnson & Johnson said its Janssen Pharmaceutica unit will supply the UK government with its candidate known as Ad26.COV2.S with an initial sale of 30 million doses on a not-for-profit basis for emergency pandemic use. (Smout and Mason, 8/14)

More response to Russia's vaccine —

CNN: Russia Offers To Help US With Covid-19 Vaccine; US Says No 

Russian officials in Moscow tell CNN they have offered "unprecedented cooperation" with Operation Warp Speed (OWS), the US multi-agency body set up to accelerate access to effective Covid-19 vaccines and treatments. But the officials told CNN that the "US is not currently open" to the Russian medical advances. (Chance, Ullah and Salama, 8/13)

PBS NewsHour: Fauci Says Despite Upcoming Election, Science Will Not Be Politicized 

Dr. Anthony Fauci, the nation’s top infectious disease expert, urged caution on Thursday as countries race to develop an effective vaccine for COVID-19, the disease caused by the novel coronavirus. “Just to say you have a vaccine doesn’t mean that you should be administering the vaccine,” Fauci said of Russia’s recent decision to approve a vaccine, which was met with skepticism by the scientific community. (Woodruff and Vinopal, 8/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
  • Tuesday, April 14
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF